Phase 1 - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Phase 1

NIOVF, OTC

#Phase 1

Plato Gold Reports on Final Results of Phase I Exploration Program for the Pic River PGE-Cu Project

February 23, 2023
07:15

EST

Toronto, Feb. 23, 2023 (GLOBE NEWSWIRE) — Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX) is pleased to report the final results from its Phase 1 exploration program completed in November 2022 on the Pic River PGE-Cu Project. The property is located 30 km northwest

No Comments

AVIR, NASDAQ

#Phase 1

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

February 23, 2023
07:00

EST

Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that data from three Phase 1 studies suggest a favorable drug-drug interaction profile. No dosage adjustment

No Comments

OTC, SKYE

#Cannabis #Phase 1 #Positive Clinical Trial Results

Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study

February 23, 2023
07:00

EST

San Diego, California–(Newsfile Corp. – February 23, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received a positive recommendation following a pre-specified data review by the safety review committee (“SRC”) based on dosing

No Comments

DARE, NASDAQ

#Phase 1

Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

February 22, 2023
08:00

EST

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID),

No Comments

IMCR, NASDAQ

#Cancer #New Clinical Trial Data #Phase 1

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV

February 22, 2023
07:00

EST

Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV Data from the single ascending dose part of the Phase 1 trial shows IMC-M113V is well tolerated Expected markers of T cell activation observed in half of participants at

No Comments

AMEX, PHGE

#Phase 1 #Positive Clinical Trial Results #Trending News

BiomX Announces Positive Results from Part 1 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

February 22, 2023
06:30

EST

BX004 therapy safe and well-tolerated across all patients and dose levels Preliminary signals of efficacy also observed, with notable reductions in bacterial burden Dosing in patients in Part 2 initiated, results expected in Q3 23 Company to host webcast/cc to discuss Part 1 data today at 9:00 am ET

No Comments

KNTE, NASDAQ

#New Clinical Trial Data #Phase 1 #Production Expansion #Trending News

Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People’s Republic of China

February 21, 2023
16:05

EST

Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structure Kinnate’s cash runway still expected to fund current operations into mid-2024 Trial sites open in People’s Republic of China (PRC) and Taiwan for ongoing Phase 1 clinical trial evaluating exarafenib, a pan-RAF

No Comments

ALRN, NASDAQ

#Cancer #Phase 1 #Trending News

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

February 21, 2023
08:30

EST

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia. The primary endpoint

No Comments

NYSE, TOVX

#Phase 1 #Trending News

Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

February 16, 2023
12:05

EST

– Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb.

No Comments

AGNPF, OTC

#Letter to Shareholders #New Clinical Trial Data #Phase 1

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

February 16, 2023
07:02

EST

VANCOUVER, British Columbia, Feb. 16, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has completed dosing of the first cohort in its

No Comments

< Page1 Page2 Page3 … Page72 >

Trending News

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

02/24/2023

Tactile Systems Technology, Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock

02/23/2023

Gatos Silver Announces 2023 Production and Cost Guidance

02/23/2023

Columbia Banking System Set to Join S&P MidCap 400; Verra Mobility to Join S&P SmallCap 600

02/23/2023

MasTec Announces Fourth Quarter and Annual 2022 Financial Results

02/23/2023

Most read news

Economic forecasts are getting revised up, and people aren’t thrilled about it

02/19/2023

Fed minutes, PCE inflation, Walmart earnings: What to know this week

02/19/2023

DelphX Announces Non-Brokered Unit Financing

02/22/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account